Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis

Pulte, 2009, Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century, Blood, 113, 1408, 10.1182/blood-2008-06-164863 Ganesan, 2021, Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC), Br. J. Haematol., 193, e1, 10.1111/bjh.17268 Inaba, 2013, Acute lymphoblastic leukaemia, Lancet, 381, 1943, 10.1016/S0140-6736(12)62187-4 Stock, 2008, What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies, Blood, 112, 1646, 10.1182/blood-2008-01-130237 Stock, 2019, A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 [published correction appears in Blood, Blood, 133, 1548, 10.1182/blood-2018-10-881961 DeAngelo, 2015, Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic, Leuk Leuk, 29, 526 Toft, 2018, Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic, Leuk Leuk, 32, 606 Ramanujachar, 2007, Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials, Pedia Blood Cancer, 48, 254, 10.1002/pbc.20749 Muffly, 2019, Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?, Hematol. Am. Soc. Hematol. Educ. Program, 2019, 17, 10.1182/hematology.2019000009 Siegel, 2018, Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens, Am. J. Hematol., 93, 1254, 10.1002/ajh.25229 Kantarjian, 2004, Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia, Cancer, 101, 2788, 10.1002/cncr.20668 Thomas, 2009, Outcome for adolescents and young adults (AYA) with the hyper-CVAD (with or without rituximab) regimens for de Novo Acute Lymphoblastic Leukemia (ALL) or lymphoblastic lymphoma, Blood, 114, 3084, 10.1182/blood.V114.22.3084.3084 Rytting, 2014, Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), Cancer, 120, 3660, 10.1002/cncr.28930 Kalina, 2012, EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols, Leukemia, 26, 1986, 10.1038/leu.2012.122 Pullarkat, 2008, Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study, Blood, 111, 2563, 10.1182/blood-2007-10-116186 Terwilliger, 2017, Acute lymphoblastic leukemia: a comprehensive review and 2017 update, Blood Cancer J., 7, 10.1038/bcj.2017.53 Huguet, 2009, Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study [published correction appears in J Clin Oncol. 2009 May 20;27(15):2574. Dosage error in article text], J. Clin. Oncol., 27, 911, 10.1200/JCO.2008.18.6916 Teuffel, 2011, Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis, Leukemia, 25, 1232, 10.1038/leu.2011.84 Rausch, 2018, PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia †, Leuk. Lymphoma, 59, 617, 10.1080/10428194.2017.1349902 Beaupin, 2017, Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review, Leuk. Lymphoma, 58, 766, 10.1080/10428194.2016.1218004 Pieters, 2011, L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase, Cancer, 117, 238, 10.1002/cncr.25489 Larsen, 2016, Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from children's oncology group study AALL0232, J. Clin. Oncol., 34, 2380, 10.1200/JCO.2015.62.4544 Thomas, 2010, Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia, J. Clin. Oncol., 28, 3880, 10.1200/JCO.2009.26.9456 Dworzak, 2008, CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy, Blood, 112, 3982, 10.1182/blood-2008-06-164129 1996, Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children, Lancet, 347, 1783, 10.1016/S0140-6736(96)91615-3 Gökbuget, 2020, Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia, Leuk. Lymphoma, 61, 2665, 10.1080/10428194.2020.1780583 Kadia, 2017, Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma, Expert Rev. Hematol., 10, 1, 10.1080/17474086.2017.1262757 Candoni, 2020, Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study, Am. J. Hematol., 95, 1466, 10.1002/ajh.25957 Grigorian, 2014, Hepatotoxicity secondary to chemotherapy, J. Clin. Transl. Hepatol., 2, 95 Zhang, 2017, Chemotherapy-induced peripheral neuropathy, Biomed. Rep., 6, 267, 10.3892/br.2017.851 Boissel, 2018, Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?, Blood, 132, 351, 10.1182/blood-2018-02-778530 Rytting, 2016, Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen, Am. J. Hematol., 91, 819, 10.1002/ajh.24419 El-Cheikh, 2017, Hyper-CVAD compared with BFM-like chemotherapy for the treatment of adult acute lymphoblastic Leukemia. A retrospective single-center analysis, Clin. Lymphoma Myeloma Leuk., 17, 179, 10.1016/j.clml.2016.11.002 Rajendra, 2021, Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol, Blood Adv., 5, 1178, 10.1182/bloodadvances.2020003526 Beldjord, 2014, Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia, Blood, 123, 3739, 10.1182/blood-2014-01-547695 Gökbuget, 2012, Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies, Blood, 120, 1868, 10.1182/blood-2011-09-377713 Berry, 2017, Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic Leukemia: a meta-analysis, JAMA Oncol., 3, 10.1001/jamaoncol.2017.0580 van Dongen, 2015, Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies, Blood, 125, 3996, 10.1182/blood-2015-03-580027 Inbar, 2017, Which patients should I transplant with acute lymphoblastic leukemia?, Best. Pr. Res Clin. Haematol., 30, 249, 10.1016/j.beha.2017.07.005 Short, 2019, Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts, Am. J. Hematol., 94, 257, 10.1002/ajh.25338 Alabdulwahab, 2017, The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience, Leuk. Res, 60, 58, 10.1016/j.leukres.2017.06.010 Storring, 2009, Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen, Br. J. Haematol., 146, 76, 10.1111/j.1365-2141.2009.07712.x Damlaj, 2020, Role of allogeneic HCT as postremission therapy for transplant-eligible adult lymphoblastic leukemia/lymphoma after frontline hyper-CVAD, Clin. Lymphoma Myeloma Leuk., 20, 690, 10.1016/j.clml.2020.05.012 Ram, 2012, Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis, Am. J. Hematol., 87, 472, 10.1002/ajh.23149 Isakoff, 2013, Young adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen do not need a bone marrow transplant in first remission, Blood, 121, 5253, 10.1182/blood-2013-03-484592 Seftel, 2016, Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission, Am. J. Hematol., 91, 322, 10.1002/ajh.24285 Vignon, 2017, Graft-versus-host disease in adolescents and young adults (15-24 Years Old) after allogeneic hematopoietic stem cell transplantation for acute leukemia in first complete remission, J. Adolesc. Young Adult Oncol., 6, 299, 10.1089/jayao.2016.0060 Hough, 2016, Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003, Br. J. Haematol., 172, 439, 10.1111/bjh.13847